[
  {
    "ts": null,
    "headline": "U.S. Food and Drug Administration Approves Streamlined Patient Monitoring Requirements and Removal of REMS Programs within Bristol Myers Squibb’s Cell Therapy Labels",
    "summary": "Label updates reflect growing body of real-world evidence and regulatory confidence in the safety profile of the class of CD19- and BCMA-directed autologous CAR T cell therapies, reinforcing efforts...",
    "url": "https://finnhub.io/api/news?id=cd97bd1c33bff7effc842a83c8e4c52d9ddd22cdc9ec2cdde0d31448e0d426cf",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750975564,
      "headline": "U.S. Food and Drug Administration Approves Streamlined Patient Monitoring Requirements and Removal of REMS Programs within Bristol Myers Squibb’s Cell Therapy Labels",
      "id": 135577452,
      "image": "",
      "related": "BMY",
      "source": "Finnhub",
      "summary": "Label updates reflect growing body of real-world evidence and regulatory confidence in the safety profile of the class of CD19- and BCMA-directed autologous CAR T cell therapies, reinforcing efforts...",
      "url": "https://finnhub.io/api/news?id=cd97bd1c33bff7effc842a83c8e4c52d9ddd22cdc9ec2cdde0d31448e0d426cf"
    }
  },
  {
    "ts": null,
    "headline": "Incyte's New CEO Is A Dealmaking Machine. Will He Bring That Fervor To His New Role?",
    "summary": "Incyte stock popped Thursday after the company's board appointed Bill Meury as its new CEO, replacing Herve Hoppenot, who is retiring.",
    "url": "https://finnhub.io/api/news?id=5104b7679c96e8d088a87b9c61f37343871ec25d50c6c528c43eb0cfcbc63ad6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750946974,
      "headline": "Incyte's New CEO Is A Dealmaking Machine. Will He Bring That Fervor To His New Role?",
      "id": 135558724,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Incyte stock popped Thursday after the company's board appointed Bill Meury as its new CEO, replacing Herve Hoppenot, who is retiring.",
      "url": "https://finnhub.io/api/news?id=5104b7679c96e8d088a87b9c61f37343871ec25d50c6c528c43eb0cfcbc63ad6"
    }
  },
  {
    "ts": null,
    "headline": "Will MRK's Growing Pipeline Help Navigate the Looming Keytruda LOE?",
    "summary": "Merck's growing pipeline, with nearly 20 new launches ahead, is set to reshape its portfolio as Keytruda's 2028 patent expiry nears.",
    "url": "https://finnhub.io/api/news?id=82caef34d94f32b3dd4e2cccb04b68afc051612e59d764ccd1f6e778a3ea7d44",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750945620,
      "headline": "Will MRK's Growing Pipeline Help Navigate the Looming Keytruda LOE?",
      "id": 135560053,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Merck's growing pipeline, with nearly 20 new launches ahead, is set to reshape its portfolio as Keytruda's 2028 patent expiry nears.",
      "url": "https://finnhub.io/api/news?id=82caef34d94f32b3dd4e2cccb04b68afc051612e59d764ccd1f6e778a3ea7d44"
    }
  },
  {
    "ts": null,
    "headline": "Incyte replaces CEO Hoppenot with dealmaker Meury",
    "summary": "Bill Meury, who shepherded Karuna and Anthos to multibillion-dollar buyouts, will take over Incyte, a successful drug developer now at a crossroads.",
    "url": "https://finnhub.io/api/news?id=b527e29352539874fc5a64f2f1644596e0d390343cf949980550ef2050c46ffe",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750940100,
      "headline": "Incyte replaces CEO Hoppenot with dealmaker Meury",
      "id": 135564480,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Bill Meury, who shepherded Karuna and Anthos to multibillion-dollar buyouts, will take over Incyte, a successful drug developer now at a crossroads.",
      "url": "https://finnhub.io/api/news?id=b527e29352539874fc5a64f2f1644596e0d390343cf949980550ef2050c46ffe"
    }
  },
  {
    "ts": null,
    "headline": "Incyte Names Bill Meury CEO as Herve Hoppenot Retires",
    "summary": "Incyte Names Bill Meury CEO as Herve Hoppenot Retires",
    "url": "https://finnhub.io/api/news?id=f0c220c5c185801f148d7c0e6131b955e7c89168e8f3ef9d6de54f683403bfca",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750924740,
      "headline": "Incyte Names Bill Meury CEO as Herve Hoppenot Retires",
      "id": 135565666,
      "image": "",
      "related": "BMY",
      "source": "MarketWatch",
      "summary": "Incyte Names Bill Meury CEO as Herve Hoppenot Retires",
      "url": "https://finnhub.io/api/news?id=f0c220c5c185801f148d7c0e6131b955e7c89168e8f3ef9d6de54f683403bfca"
    }
  }
]